Company Overview
Snapshot
Founded in August 2013 by Amit Dar, Neurolief operates with 11–50 employees. The company has raised $17.05M across 4 funding rounds from 5 investors. In January 2026, Neurolief received FDA PMA approval for its at-home brain neuromodulation therapy for adults with depression.
Business overview
Neurolief develops treatments for patients with chronic neurological and neuropsychiatric disorders, focusing on a digital therapeutics platform of clinically proven neuromodulation-based solutions. Its core product, Relivion, is a noninvasive multichannel brain neuromodulation system that delivers precise, personalized care by stimulating occipital and trigeminal nerves. This technology aims to modulate brain networks associated with pain and mood control, serving markets in Health Tech & Life Sciences, particularly in digital healthcare and digital therapeutics.
Strategic signal
In January 2026, Neurolief received FDA PMA approval for its at-home brain neuromodulation therapy for adults whose depression was not adequately improved by antidepressants. This approval is a significant regulatory milestone, validating the company's technology for a broader application beyond migraine treatment and signaling strong potential for market expansion in mental health care.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant regulatory achievement for Neurolief in early 2026?
- In January 2026, Neurolief received FDA PMA approval for its at-home brain neuromodulation therapy, specifically for adults whose depression was not adequately improved by antidepressants.
- What strategic investment did Neurolief receive in August 2025?
- In August 2025, BrainsWay made a strategic investment in Neurolief to expand its total addressable market in mental health care.
- What clinical study results did Neurolief present in October 2024?
- In October 2024, Neurolief presented groundbreaking study results of its ProlivRx brain neuromodulation therapy for treating major depression at the 7th Annual Neuropsychiatric Drug Summit.
- When did Neurolief receive FDA clearance for its Relivion wearable technology for migraine treatment?
- In March 2021, Neurolief's Relivion wearable brain neuromodulation technology was cleared by the FDA for the treatment of migraine.
- What international licensing agreement did Neurolief announce in July 2021?
- In July 2021, Neurolief announced an exclusive licensing agreement with NeuroFront for the development and commercialization of Relivion in Greater China and South Korea.